transcodetherapeutics.com (RNAZ): Long-Term Debt to Capital Ratio

TransCode Therapeutics, Inc. (RNAZ) - corporate logo

TransCode Therapeutics (RNAZ) is actively recruiting leading chemists to develop oncology drug delivery systems, incentivizing staff with stock options. The business's competitiveness is based on targeted therapy patents, although ultimate success depends on clinical trials. This price chart on GURU.Markets, where the metric is 0.00, complements data on the implementation of eco-friendly production methods and chemical recycling.

Long-Term Debt to Equity Ratio: TransCode Therapeutics Inc. (RNAZ) for 07/04/2022 - 10/27/2026

Comprehensive metric breakdowns and analytics for TransCode Therapeutics Inc. (RNAZ)

- price and consensus price forecast:
Share Price TransCode|RNAZ - Price Target Chart
- market capitalization data:
Market Capitalization TransCode Therapeutics, Inc.|RNAZ - Enterprise Value
- book capitalization data:
Book Value per Share TransCode Therapeutics|RNAZ - Company Net Assets|Market Cap to Book Value Multiple transcodetherapeutics.com|RNAZ - Aggregate Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio TransCode Therapeutics|RNAZ - Long-Term Debt to Capital|Short-Term Debt to Capital TransCode|RNAZ - Company Debts|Debt to Book Value Ratio TransCode Therapeutics, Inc.
Fundamental company analysis:transcodetherapeutics.com
Core merchandise of TransCode Therapeutics Inc.

Finding a balance between asset quality and market value requires an analysis of long-term financial leverage. This indicator correlates liabilities with maturities exceeding one year against equity, revealing the actual financing structure. For TransCode Therapeutics (RNAZ), with its single-product focus on an RNA platform, this is critical due to binary development risks. An absence of debt capital may mask declining profitability. The dynamics of the long-term debt-to-equity structure make it possible to isolate the impact of share issuances from business revaluation.

Direct competitors

Long-Term Debt to Capital Ratio TEM|Long-Term Debt to Equity Qiagen Group QGEN|Long-Term Debt to Capital Ratio Isis Pharmaceuticals (IONS)|Long-Term Debt to Capital RGEN (Repligen Corporation)|RNA - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio CRISPR Therapeutics CRSP|WGS: Long-Term Loans to Capital Ratio|Long-Term Debt to Equity Ultragenyx Pharma RARE|Beam Tx (BEAM) - Long-Term Debt to Capital Coefficient|SRPT (Sarepta Therapeutics, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Capital TWST|Long-Term Debt to Equity 10x Genomics TXG|Long-Term Debt to Capital Ratio NTLA (Intellia Therapeutics Inc)|Long-Term Debt to Equity STOK|Ratio of Long-Term Indebtedness to Capital BioLife BLFS|WVE: Long-Term Debt to Capital|MAZE: Long-Term Debt to Equity Ratio|Long-Term Debt to Equity SION|Prime Medicine Inc (PRME) - Long-Term Liabilities to Capital|Long-Term Debt to Capital Taysha (TSHA)|Long-Term Debt to Capital Ratio uniQure Pharma|MeiraGTx Holdings plc - Long-Term Debt to Capital|Long-Term Liabilities to Capital regenxbio.com RGNX|Long-Term Debt to Equity Ratio Solid Biosciences|OCGN - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio Pacific Biosciences of California PACB|BNTC - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital Design Therapeutics DSGN|rocketpharma.com (RCKT) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital FDMT (4D Molecular Therapeutics, Inc.)|Long-Term Liabilities to Capital LXEO|Korro Bio, Inc. (KRRO) - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient Editas Corp (EDIT)|Long-Term Debt to Capital SLN (Silence Therapeutics)|ProQR - Long-Term Debt to Capital|Long-Term Debt to Equity Codexis Bio|SGMO - Long-Term Liabilities to Equity|Long-Term Debt to Capital NAUT|Long-Term Liabilities to Capital Metagenomi Therapeutics|DTIL (Precision BioSciences) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Generation Bio Corp (GBIO)|Long-Term Debt to Equity Ratio Boundless Bio|Long-Term Loans to Capital Ratio exicuretx.com (XCUR)|Long-Term Debt to Capital IMNN|Ratio of Long-Term Indebtedness to Capital Phio Pharmaceuticals Corp PHIO|MBIO: Long-Term Debt to Capital|BNGO: Long-Term Debt to Equity Ratio|Applied DNA Sciences, Inc. - Long-Term Debt to Equity|BLUE (bluebird bio Inc.) - Ratio of Long-Term Indebtedness to Capital|IPA - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient OMGA|Long-Term Debt to Equity Singular Genomics Systems OMIC|Long-Term Debt to Capital Ratio regulusrx.com (RGLS)|Long-Term Debt to Capital SYRS (Syros Pharmaceuticals, Inc.)|TBIO - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio TRACON|UBX - Long-Term Liabilities to Equity